8-KOther Events

BIOGEN INC. 8-K Report (Jun 23, 2003)

Filed June 23, 2003For Securities:BIIB

Summary

On June 23, 2003, IDEC Pharmaceuticals Corporation announced a significant development: a definitive merger agreement with Biogen, Inc. This all-stock transaction will combine the two biotechnology companies, with IDEC shareholders set to own 50.5% of the merged entity and Biogen shareholders owning 49.5%. This move signals a major strategic consolidation within the biopharmaceutical industry, aiming to leverage the strengths of both companies. The merger is contingent upon the approval of both companies' stockholders and regulatory bodies, with an anticipated completion in late Q3 or early Q4 2003. IDEC has also amended its Rights Agreement to clarify that Biogen's common stock holders will not be considered beneficial owners of IDEC's shares prior to the transaction's effectiveness. Investors should closely monitor the shareholder approval process and any further regulatory updates.

Key Highlights

  • 1IDEC Pharmaceuticals and Biogen have signed a definitive merger agreement.
  • 2The transaction is an all-stock deal, combining two biotechnology companies.
  • 3Upon completion, IDEC shareholders will own 50.5% of the combined company, and Biogen shareholders will own 49.5%.
  • 4Completion of the merger is subject to stockholder and regulatory approvals.
  • 5The parties anticipate the transaction will close in late Q3 or early Q4 2003.
  • 6IDEC has amended its Rights Agreement to address beneficial ownership implications for Biogen shareholders.
  • 7A registration statement on Form S-4 will be filed by IDEC to register the shares issued in the transaction.

Frequently Asked Questions

This 8-K filing announces that IDEC Pharmaceuticals Corporation and Biogen, Inc. have entered into a merger agreement, detailing the terms of their combination into a single entity.

The merger is structured as an all-stock transaction. IDEC will issue 1.15 shares of its common stock for each outstanding share of Biogen common stock. Post-merger, IDEC shareholders will hold 50.5% of the combined company, with Biogen shareholders holding 49.5%.

The merger is subject to several conditions, including approval from the stockholders of both IDEC and Biogen, as well as necessary regulatory approvals and other standard closing conditions.

The companies anticipate that the transaction will be completed by the end of the third quarter or early in the fourth quarter of 2003.